Podcast

Dr. Laviana on decisional regret after prostate cancer treatment

Author(s):

Urology Times staff

“Localized prostate cancer is a very complicated disease space,” says Aaron A. Laviana, MD, MBA.

In this episode, Urology Times® spoke with Dr. Aaron Laviana, who discusses decisional regret in patients with prostate cancer. Laviana is an assistant professor of surgery and perioperative care and a courtesy faculty member of the department of oncology at The University of Texas at Austin Dell Medical School.

Related Videos
Alicia Morgans, MD, MPH, answers a question during a Zoom video interview
Vanita Gaglani, RPT, answers a question during a video interview
Blur image of hospital corridor | Image Credit: © whyframeshot - stock.adobe.com
Channing J. Paller, MD, answers a question during a Zoom video interview
Vanita Gaglani, RPT, answers a question during a video interview
Channing J. Paller, MD, answers a question during a Zoom video interview
Related Content
Man talking with doctor | Image Credit: © rocketclips - stock.adobe.com
February 19th 2025

WOLVERINE findings highlight benefits of MDT in oligometastatic prostate cancer

Benjamin P. Saylor
Median PFS was 35 months in the MDT plus SOC group vs 21 months in the SOC alone group.
Episode 3 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management
February 11th 2025

Episode 3 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS
Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.
Prostate cancer, 3D illustration showing presence of tumor inside prostate gland which compresses urethra | © Dr_Microbe - stock.adobe.com
February 14th 2025

Darolutamide plus ADT shows mHSPC benefit regardless of disease volume

Benjamin P. Saylor
"Efficacy outcomes with darolutamide plus ADT were improved vs placebo plus ADT regardless of disease volume," said Fred Saad, MD, FRCS.
Episode 2 Podcast: Identifying Patients with Intermediate Risk in NMIBC
January 29th 2025

Episode 2 Podcast: Identifying Patients with Intermediate Risk in NMIBC

Max Kates, MD Neal Shore, MD, FACS Tom Jayram, MD
Panelists explore challenges in identification of intermediate risk patients and emphasize importance of risk stratification to improve outcomes in regards to NMIBC.
Blur image of hospital corridor | Image Credit: © whyframeshot - stock.adobe.com
February 13th 2025

Darolutamide is safe, efficacious in mHSPC regardless of patient age

Benjamin P. Saylor
"Patients with metastatic hormone-sensitive prostate cancer benefited from treatment with darolutamide plus ADT and docetaxel regardless of age," said Joan Carles, MD, PhD.
Conceptual image for prostate cancer treatment, 3D illustration showing destruction of a tumor inside prostate gland | © Dr_Microbe - stock.adobe.com
February 13th 2025

Race subgroup analysis points to clinical benefit of darolutamide in nmCRPC

Benjamin P. Saylor
In both racial cohorts, median MFS was not reached in the darolutamide group.
© 2025 MJH Life Sciences

All rights reserved.